APLS
HEALTHCAREApellis Pharmaceuticals Inc
AI Insight
What's Moving APLS Today?
No stock-specific AI insight has been generated for APLS yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring APLS
52-Week Range
$3.48$41.14
$41.12
Fundamentals
Market Cap$5.3B
P/E Ratio38.4
EPS$1.07
Dividend Yield—
Dividend / Share—
ROE46.0%
Profit Margin12.1%
Debt / Equity—
Trading
Volume3.7M
Avg Volume (10D)—
Shares Outstanding128.0M
APLS News
29 articles- Biogen Stock Slides After Trial Miss, But Analysts Stay BullishMarketbeat·May 22, 2026
- Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond PriceYahoo Finance·May 18, 2026
- RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS)Stock Titan·May 15, 2026
- Biogen completes $5.3B Apellis Pharmaceuticals acquisitionQz·May 15, 2026
- [Form 4] Apellis Pharmaceuticals, Inc. Insider Trading ActivityStock Titan·May 14, 2026
- Biogen deal: Apellis (APLS) director’s shares and options cashed outStock Titan·May 14, 2026
- Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVRStock Titan·May 14, 2026
- Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swapStock Titan·May 14, 2026
- Biogen Completes Acquisition of Apellis PharmaceuticalsYahoo Finance·May 14, 2026
- Apellis (APLS) HSR waiting period expired; $41.00 cash plus up to $4.00 CVRStock Titan·May 12, 2026
- Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600Yahoo Finance·May 7, 2026
- Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 7, 2026
- Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·May 7, 2026
- ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·May 1, 2026
- Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·Apr 29, 2026
- Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?Yahoo Finance·Apr 24, 2026
- OCGN's Gene-Agnostic Strategy Could Reset Retinal TherapyYahoo Finance·Apr 22, 2026
- Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy AllianceYahoo Finance·Apr 19, 2026
- Gilead Expands Oncology Pipeline With $5B Tubulis DealYahoo Finance·Apr 9, 2026
- Biogen Taps Alloy Platform To Push Antisense Drug Pipeline ForwardBenzinga·Apr 7, 2026
- Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation StoryYahoo Finance·Apr 4, 2026
- Where the New Houses Are—and What That Says About GrowthYahoo Finance·Apr 3, 2026
- Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers BankruptcyBenzinga·Apr 3, 2026
- Here Are Thursday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Astra-Zeneca, Brinker, e.l.f. Beauty, Freeport-McMoran, Vale, Wingstop, Wix.com, and More247 Wall St·Apr 2, 2026
- How The Apellis Pharmaceuticals (APLS) Investment Story Is Shifting With New Deals And Analyst RevisionsYahoo Finance·Apr 1, 2026
- Biogen to Acquire Apellis for $5.6B to Strengthen Immunology PortfolioYahoo Finance·Apr 1, 2026
- Disney upgraded, Nike downgraded: Wall Street's top analyst callsYahoo Finance·Apr 1, 2026
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boeing, Datadog, Disney, Formula One Group, Nike, Rivian, Rocket Lab, ServiceNow, and More247 Wall St·Apr 1, 2026
- Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis DealBenzinga·Mar 31, 2026
All 29 articles loaded
Price Data
Open$0.00
Previous Close$40.97
Day High$0.00
Day Low$0.00
52 Week High$41.14
52 Week Low$3.48
52-Week Range
$3.48$41.14
$41.12
Fundamentals
Market Cap$5.3B
P/E Ratio38.4
EPS$1.07
Dividend Yield—
Dividend / Share—
ROE46.0%
Profit Margin12.1%
Debt / Equity—
Trading
Volume3.7M
Avg Volume (10D)—
Shares Outstanding128.0M
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—